US Transcatheter Aortic Valve Replacement (TAVR) Market Size Worth USD 4,000 Million by 2034

The US transcatheter aortic valve replacement (TAVR) market size surpassed USD 2,029 million in 2024 and is predicted to reach around USD 4,000 million by 2034, registering a CAGR of 7.02% from 2025 to 2034.

Highlights of the US Transcatheter Aortic Valve Replacement (TAVR) Market

• By implantation procedure, the transfemoral segment dominated the market in 2024.
• By implantation procedure, the transapical segment is anticipated to grow at the fastest rate in the market.
• By material, the nitinol segment dominated the market in 2024.
• By material, the cobalt-chromium segment is anticipated to grow at the fastest rate in the market.
• By mechanism, the balloon-expanding segment dominated the U.S. transcatheter aortic valve replacement (TAVR) market in 2024.
• By mechanism, the self-expanding valve segment is anticipated to grow at the fastest rate in the market.
• By end-use, the hospitals segment dominated the market in 2024.
• By end-use, the ambulatory surgical centers segment is anticipated to grow at the fastest rate in the U.S. market.

Industry Valuation and Growth Rate Projection

U.S. transcatheter aortic valve replacement is a surgical method that includes replacing a defective aortic valve without extracting it. A valve replacement generally necessitates an open-heart surgery with a sternotomy, in which the chest is surgically opened for the procedure. Still, the TAVI is performed via tiny holes, leaving all the chest bones in their place. Meanwhile, the U.S. transcatheter aortic valve replacement (TAVR) market incorporates implanting transaortic valves or transcatheter aortic valves to regenerate the valve’s circulatory system capabilities, one of the many advancements in the sector. It is mainly used to treat patients having aortic stenosis.

What Are the Market Trends in the U.S. Transcatheter Aortic Valve Replacement (TAVR) Market?

• The market is growing in the U.S. due to the unique benefits of transcatheter aortic valve replacement (TAVR) minimally invasive nature, faster recovery times, and expanding approval for use across broader patient risk categories, including intermediate and high-risk cases.
• TAVR provides a less invasive option to traditional open-heart surgery, contributing to shorter recovery times and decreased risks, making it a preferred option for many patients.
• TAVR has been accepted for numerous risk categories, including intermediate-risk and high-risk patients, and valve-in-valve procedures, thus contributing to market expansion.

What Are the Restraints in the U.S. Transcatheter Aortic Valve Replacement (TAVR) Market?

• Limited awareness among certain patient groups, competition from traditional surgical options like SAVR, and inconsistent insurance coverage policies are key factors restraining wider adoption of transcatheter aortic valve replacement.
• In some areas, especially amongst older populations, there may be a shortage of awareness about the advantages and availability of TAVR, hampering adoption.
• Surgical Aortic Valve Replacement (SAVR) is still a viable alternative, especially for lower-risk patients. The continued existence of SAVR can limit the growth of the TAVR market.
• Though Medicaid and Medicare cover TAVR under a national policy, coverage policies can vary among private insurance firms, which can be a barrier for some.

What Are the Opportunities in the U.S. Transcatheter Aortic Valve Replacement (TAVR) Market?

Opportunities include a rising elderly population with aortic valve disease, advancements in valve technology and delivery systems, and expanded access through improved healthcare infrastructure and minimally invasive treatment options.

• The aging population is undergoing a higher incidence of aortic valve disease, contributing to increased requirements for TAVR procedures.
• Improved healthcare infrastructure and access to developed technologies, mainly in developing markets, are also leading to market growth.
• Ongoing innovation in valve programmed and delivery systems is enhancing TAVR's safety and efficacy. This includes developments in valve durability, lessened complication rates, and better patient results.

Recent Developments in the U.S. Transcatheter Aortic Valve Replacement (TAVR) Market

• In May 2025, Edwards Lifesciences disclosed that the U.S. Food and Drug Administration (FDA) has accepted its transcatheter+6 aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) without symptoms, marking the first FDA acceptance for TAVR in asymptomatic patients.